一种DNA聚合酶theta抑制剂及其应用
By providing a novel DNA polymerase theta inhibitor, the problem of the single structure of existing inhibitors is solved, and effective inhibition of Polθ is achieved, which has the potential for anti-cancer therapy, especially in reducing the risk of cell death in the case of BRCA1 or BRCA2 mutations.
CN118451067BActive Publication Date: 2026-07-17SHANGHAI APEIRON THERAPEUTICS CO LTD
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SHANGHAI APEIRON THERAPEUTICS CO LTD
- Filing Date
- 2022-12-30
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing Polθ inhibitors have relatively simple structures and cannot effectively inhibit the activity of DNA polymerase theta.
Method used
A novel DNA polymerase theta inhibitor is provided, comprising compounds whose structures are represented by specific chemical formulas II or III, and their pharmaceutically acceptable salts or solvates, which can effectively inhibit the activity of Polθ.
Benefits of technology
This inhibitor can significantly suppress the activity of Polθ and has potential anti-cancer therapeutic effects, especially in the case of HR deficiency caused by BRCA1 or BRCA2 mutations, reducing the accumulation of toxic RAD51 intermediates and reducing the risk of cell death.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN118451067B_ABST
Abstract
本发明公开了一种DNA聚合酶theta抑制剂及其应用。本发明具体提供了如式(I)或式(II)所示的化合物，或其互变异构体、其立体异构体、前述任一者的药学上可接受的盐或前述任一者的溶剂合物。其对Polθ有较好的抑制作用。
Need to check novelty before this filing date? Find Prior Art